Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective matched cohort study of immune checkpoint inhibitors and vascular inflammation in stage III melanoma
NL-OMON51479Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of ipilimumab, nivolumab and pembrolizumab, sponsored by Leiden University Medical Center. Started Sep 2022; status: recruiting.
02
Drugs
Beyond the preview
Go deeper on NL-OMON51479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51479.